Wall Street analysts expect Allergan (NYSE:AGN) to report $3.59 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Twenty Two analysts have made estimates for Allergan’s earnings, with estimates ranging from $3.53 billion to $3.65 billion. Allergan posted sales of $3.57 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 0.6%. The firm is scheduled to report its next quarterly earnings results before the market opens on Monday, April 30th.
On average, analysts expect that Allergan will report full-year sales of $3.59 billion for the current fiscal year, with estimates ranging from $15.03 billion to $15.36 billion. For the next year, analysts expect that the company will report sales of $15.65 billion per share, with estimates ranging from $14.88 billion to $16.38 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Allergan.
Allergan (NYSE:AGN) last issued its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.74 by $0.12. Allergan had a positive return on equity of 8.43% and a negative net margin of 26.32%. The company had revenue of $4.33 billion for the quarter, compared to analysts’ expectations of $4.28 billion. During the same period last year, the business earned $3.90 EPS. Allergan’s quarterly revenue was up 12.0% compared to the same quarter last year.
Several equities analysts have weighed in on AGN shares. Cantor Fitzgerald set a $191.00 price objective on Allergan and gave the company a “hold” rating in a research note on Thursday. Deutsche Bank restated a “buy” rating on shares of Allergan in a research note on Thursday. Royal Bank of Canada set a $218.00 price objective on Allergan and gave the company a “buy” rating in a research note on Thursday, January 4th. ValuEngine cut Allergan from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Citigroup dropped their price objective on Allergan to $215.00 and set a “buy” rating on the stock in a research note on Tuesday, January 9th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $224.02.
In other news, Director Joseph H. Boccuzi acquired 900 shares of the firm’s stock in a transaction that occurred on Monday, March 5th. The stock was bought at an average price of $143.42 per share, with a total value of $129,078.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Maria Teresa Hilado acquired 895 shares of the firm’s stock in a transaction that occurred on Thursday, March 15th. The stock was purchased at an average cost of $167.39 per share, with a total value of $149,814.05. The disclosure for this purchase can be found here. Insiders have bought a total of 8,095 shares of company stock worth $1,258,081 over the last quarter. Company insiders own 0.36% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in AGN. Avestar Capital LLC purchased a new stake in Allergan in the 4th quarter worth about $113,000. Focused Wealth Management Inc increased its holdings in Allergan by 4,444.4% in the 4th quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock worth $134,000 after acquiring an additional 800 shares during the last quarter. Acropolis Investment Management LLC purchased a new stake in Allergan in the 4th quarter worth about $153,000. Field & Main Bank purchased a new stake in Allergan in the 4th quarter worth about $155,000. Finally, Captrust Financial Advisors purchased a new stake in Allergan in the 4th quarter worth about $175,000. 77.95% of the stock is owned by institutional investors.
Shares of AGN traded up $1.25 during trading hours on Tuesday, reaching $166.31. The stock had a trading volume of 1,038,476 shares, compared to its average volume of 3,175,412. Allergan has a 12 month low of $142.81 and a 12 month high of $256.80. The company has a quick ratio of 1.06, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The stock has a market cap of $57,496.78, a P/E ratio of 10.17, a P/E/G ratio of 1.18 and a beta of 1.18.
The firm also recently announced a quarterly dividend, which was paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th were paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.73%. This is a boost from Allergan’s previous quarterly dividend of $0.70. The ex-dividend date was Tuesday, February 27th. Allergan’s payout ratio is presently 17.61%.
TRADEMARK VIOLATION NOTICE: “Allergan (AGN) Expected to Announce Quarterly Sales of $3.59 Billion” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://ledgergazette.com/2018/04/20/allergan-agn-expected-to-announce-quarterly-sales-of-3-59-billion.html.
Allergan Company Profile
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.